Search

Displaying results 3301 - 3310 of 8517 in total
  1. Drug

    Benfluorex

    go.drugbank.com/drugs/DB09022
    ApprovedWithdrawn

    This recommendation was based on the risks (especially fenfluramine-like cardiovascular side-effects) outweighing the benefits. … It was patented and manufactured by a French pharmaceutical company Servier. The European Medicines Agency (EMA) recommended withdrawing all benfluorex containing medicines on 18 December 2009.

  2. Drug

    NM-702

    go.drugbank.com/drugs/DB05505
    Investigational

    In the USA, a Phase 2 study for intermittent claudication caused by arteriosclerosis obliterans has been successfully completed. … It is caused by insufficient oxygen supply to exercising muscles in the lower extremities due to decreased blood flow as a result of sclerosis of peripheral arteries.

  3. Drug

    Casimersen

    go.drugbank.com/drugs/DB14984
    ApprovedInvestigational

    A related, albeit a less severe, form of muscular dystrophy known as Becker muscular dystrophy (BMD) is characterized by shortened and partially functional dystrophin protein production. … Casimersen was granted accelerated FDA approval on February 25, 2021, based on data showing an increase in dystrophin levels in skeletal muscle of patients treated with casimersen; this approval is contingent

  4. Drug

    Datopotamab deruxtecan

    go.drugbank.com/drugs/DB16410
    ApprovedInvestigational

    [L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.

  5. Drug

    Human cytomegalovirus immune globulin

    go.drugbank.com/drugs/DB13886
    ApprovedInvestigational

    The transmission of cytomegalovirus infection requires intimate contact with infected excretions such as saliva, urine, cervical and vaginal excretions, semen, breast milk and blood [L2228]. … As a consequence, CMV disease is restricted to the immunocompromised or immunologically immature host, in which it can lead the devastating result of transplant rejection [A32498], [L2229].

  6. Drug

    Human cord blood hematopoietic progenitor cell

    go.drugbank.com/drugs/DB11054
    Approved

    Hemacord is marketed in the U.S. as an allogeneic cord blood hematopoietic progenitor cell therapy for intravenous use. … After the first cord blood transplant in 1988 in a patient with Fanconi anemia [A32220], the use of umbilical cord blood transplantation was increased in clinical settings.

  7. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval.

  8. Drug

    Terizidone

    go.drugbank.com/drugs/DB12954
    ApprovedInvestigationalWithdrawn

    Terizidone has been used in trials studying the treatment of Tuberculosis, HIV Infections, Multidrug Resistant Tuberculosis, and Extensively-drug Resistant Tuberculosis.

  9. Drug

    Ferric carboxymaltose

    go.drugbank.com/drugs/DB08917
    ApprovedInvestigational

    It was FDA approved on July 25, 2013.

  10. Drug

    Sultamicillin

    go.drugbank.com/drugs/DB12127
    ApprovedWithdrawn

    Sultamicillin has been used in trials studying the prevention and treatment of Ventilator Associated Pneumonia and Chronic Obstructive Pulmonary Disease (COPD).